XBiotech (XBIT) Stock Price, News & Analysis

Company Overview

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Key Stats

• Today's Range: $2.81 to $2.96
• 50-Day Range: $2.77 to $3.48
• 52-Week Range: $2.65 to $8.64
• Volume: 39,527 shs
• Average Volume: 75,687 shs
• Market Capitalization: $86.59 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

XBiotech Stock Analysis - MarketRank™

XBiotech scored higher than 8% of companies evaluated by MarketBeat, and ranked 890th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for XBiotech.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of XBiotech is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of XBiotech is -2.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

XBiotech has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.61% of the float of XBiotech has been sold short.

Short Interest Ratio / Days to Cover

XBiotech has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.

Change versus previous month

Short interest in XBiotech has recently increased by 28.81%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

XBiotech does not currently pay a dividend.

Dividend Growth

XBiotech does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.61% of the float of XBiotech has been sold short.

Short Interest Ratio / Days to Cover

XBiotech has a short interest ratio ("days to cover") of 16.2, which indicates bearish sentiment.

Change versus previous month

Short interest in XBiotech has recently increased by 28.81%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.4 / 5
• News Sentiment: N/A

News Sentiment

XBiotech has a news sentiment score of 0.58. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, XBiotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

33.10% of the stock of XBiotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

55.70% of the stock of XBiotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XBIT Stock Analysis - Frequently Asked Questions

How have XBIT shares performed this year?

XBiotech's stock was trading at $3.95 at the beginning of the year. Since then, XBIT stock has decreased by 28.1% and is now trading at $2.84.
View the best growth stocks for 2025 here.

How were XBiotech's earnings last quarter?

XBiotech Inc. (NASDAQ:XBIT) announced its quarterly earnings results on Wednesday, May, 14th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter.

When did XBiotech IPO?

XBiotech (XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co acted as the underwriter for the IPO.

Who are XBiotech's major shareholders?

XBiotech's top institutional investors include American Century Companies Inc. (0.33%), Charles Schwab Investment Management Inc. (0.22%), Connor Clark & Lunn Investment Management Ltd. (0.21%) and Goldman Sachs Group Inc. (0.15%).
View institutional ownership trends.

How do I buy shares of XBiotech?

Shares of XBIT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some other companies that XBiotech investors own include Voyager Therapeutics (VYGR), American Water Works (AWK), The RMR Group (RMR), Waste Connections (WCN), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC) and AUO (AUOTY).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 5/24/2025
• Next Earnings (Estimated): 8/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:XBIT
• CIK: 1626878
• Web: www.xbiotech.com
• Phone: (512) 386-2900
• Fax: 512-386-5505
• Employees: 100
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.29)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-24,560,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -15.99%
• Return on Assets: -14.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.57
• Quick Ratio: 11.57

Sales & Book Value

• Annual Sales: $4.01 million
• Price / Sales: 21.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.19 per share
• Price / Book: 0.39

Miscellaneous

• Outstanding Shares: 30,488,000
• Free Float: 20,393,000
• Market Cap: $86.59 million
• Optionable: Optionable
• Beta: 0.98